Iterative Health’s Site Network Model Cuts Trial Timelines by 3 Months
Event summary
- Iterative Health published research at ECCO 2026 showing its site network model accelerates trial execution.
- Sites in the network enrolled patients at 0.34 per month, 3.4x industry benchmarks.
- Activation timelines were reduced to a median of 74 days vs. 120–171 days in traditional models.
- The study evaluated performance across ulcerative colitis and Crohn’s disease trials in the U.S. and Europe.
The big picture
Iterative Health’s data highlights a growing trend toward decentralized, technology-enabled clinical research. The model addresses longstanding inefficiencies in trial execution, particularly in complex disease areas like inflammatory bowel disease (IBD). If scalable, this approach could reshape the $50B+ global CRO market by shifting power dynamics from sponsors to high-performing site networks.
What we're watching
- Scalability Challenge
- Whether Iterative Health can sustain performance metrics as it expands into new therapeutic areas.
- Competitive Differentiation
- How this model will position the company against traditional contract research organizations (CROs).
- Regulatory Alignment
- The pace at which regulators may adapt guidelines to accommodate site-centric, AI-driven trial models.
Our editorial coverage: